Le rapport
Analyses approfondies du financement des entreprises, des stratégies de croissance et des insights de marché des entreprises les plus innovantes du monde
25 rapports et plus encore
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Biotech startup Diagonal Therapeutics secures $125 million Series B for rare genetic disease treatments.
Bambusa Therapeutics raises $90M Series A at $400M valuation
Bambusa Therapeutics raises $90M in Series A at $400M valuation. Bispecific antibodies for immunology...
Star Therapeutics raises $125M Series B at $600M valuation
Star Therapeutics raises $125M in Series B at $600M valuation. Antibody therapies for cancer...
AbCellera raises $555M Series B at $5.7B valuation
AbCellera raises $555M in Series B at $5.7B valuation. Antibody discovery platform...
Abcuro raises $200M Series C at $1.5B valuation
Abcuro raises $200M in Series C at $1.5B valuation. Antibody therapeutics for autoimmune diseases...
Star Therapeutics raises $125M Series D
Star Therapeutics raises $125M in Series D. Developing antibody therapies for autoimmune and inflammatory diseases...
ProfoundBio Raises $112M Series B
Clinical-stage oncology company developing antibody-drug conjugates (ADCs) for targeted cancer therapy
Upstream Bio raises $153M Series B at $800M valuation
Upstream Bio raises $153M in Series B at $800M valuation. Developing antibody therapeutics for inflammatory diseases...
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Affichage de 9 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.